WP
SION

Woodline Partners’s Sionna Therapeutics SION Stock Holding History

Woodline Partners’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-80,000
Closed -$1.39M – 1079
2025
Q2 		$1.39M Hold
80,000
– – 0.01% 771
2025
Q1 		$837K Buy
+80,000
New +$1.31M 0.01% 782

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Woodline Partners's SION Position: Q3 2025 in Review

Woodline Partners sold out of Sionna Therapeutics (SION) in Q3 2025, closing a stake of 80,000 shares — an estimated $1.39M sold.

Woodline Partners first reported a position in SION in Q1 2025 and held it in 2 quarters. The position peaked at $1.39M in Q2 2025. 78 funds tracked by Wall St. Rank hold SION as of Q3 2025.

  • Woodline Partners reported no remaining Sionna Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Woodline Partners sold 80,000 Sionna Therapeutics shares in Q3 2025, an estimated $1.39M.
  • Woodline Partners first reported a position in Sionna Therapeutics in Q1 2025 and held it in 2 quarters.
  • Woodline Partners's Sionna Therapeutics position peaked at $1.39M in Q2 2025.
  • 78 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q3 2025.

Based on Woodline Partners's 13F filing for Q3 2025, filed 14 Nov 2025.